Price increases are the biggest driver of rising emergency room visit costs across the U.S., according to research led by the Center for Health and Biosciences' Vivian Ho and Sasathorn Tapaneeyakul.
Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).
The unproven stem cell intervention industry is a worldwide, direct-to-consumer market where clinics offer stem cells or stem cell-derived components to patients with little to no scientific or clinical basis. In this paper, the authors call for the establishment of a World Health Organization Expert Advisory Committee on Regenerative Medicine to tackle this issue and provide guidance. Stem Cell Reports: https://doi.org/10.1016/j.stemcr.2021.05.004
The results of this study suggest that Medicare Data on Provider Practice and Specialty, which costs less to obtain than from a for-profit data source, can be used to reliably track the cost and quality effects of vertical integration between hospitals and physicians.
Using China Customs port-level export data, this article analyzes the key outlet points for China’s middle distillate exports and into what markets they are being sold.
Gabriel Collins, Andrew S. EricksonNovember 14, 2016